{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:54:18Z","timestamp":1769208858416,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,10,17]],"date-time":"2006-10-17T00:00:00Z","timestamp":1161043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:p>We treated elderly patients with relapsed or refractory peripheral T\u2010cell lymphoma (PTCL) using a CMD (CPT\u201011, mitoxantrone [MIT], dexamethasone [DEX]) regimen and studied its safety and efficacy. The subjects were 70\u201379\u2010year\u2010old patients with relapsed or refractory PTCL. CPT\u201011 at 25\u00a0mg\/m<jats:sup>2<\/jats:sup> on days 1 and 2, MIT at 8\u00a0mg\/m<jats:sup>2<\/jats:sup> on day 3, and DEX at 40\u00a0mg\/day on days 1\u20133 were administered once every 3 weeks, and this was performed for six cycles. Eleven (37%) of the 30 patients achieved complete remission and seven patients (23%) achieved partial remission. With a median follow\u2010up period of 32\u00a0months, the 3\u2010year survival rate was 28.2% and the 3\u2010year progression\u2010free survival rate was 17.5%. The main adverse drug reaction was hematological toxicity and there were no deaths related to the treatment. B\u2010type natriuretic peptide and troponin T levels did not increase after the treatment and none of the patients showed electrocardiogram or echocardiogram abnormalities. Our results indicate that the CMD regimen is safe in elderly patients and no cardiotoxicities developed as a result of this regimen. In addition, it was effective in patients who had previously been treated with doxorubicin and good treatment results were obtained in elderly patients with relapsed PTCL. (<jats:italic>Cancer Sci<\/jats:italic> 2007; 98: 109\u2013112)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2006.00349.x","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T09:31:01Z","timestamp":1161163861000},"page":"109-112","source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of the irinotecan (CPT\u201011), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T\u2010cell lymphoma"],"prefix":"10.1111","volume":"98","author":[{"given":"Nozomi","family":"Niitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kohori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"e_1_2_6_3_2","first-page":"1091","volume-title":"Neoplastic Hematopathology","author":"Pinkus GS","year":"2001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V106.11.811.811","article-title":"The International PTCL Project International Peripheral T\u2010Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines","volume":"106","author":"Vose JM","year":"2005","journal-title":"Blood"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_6_6_2","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685611"},{"key":"e_1_2_6_8_2","first-page":"75","article-title":"An early phase II study of CPT\u201011 (Irinotecan hydrochloride) in patients with hematological malignancies","volume":"21","author":"Ohno R","year":"1994","journal-title":"Jpn J Cancer Chemother"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500420"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500516"},{"key":"e_1_2_6_11_2","first-page":"50","article-title":"Mitoxantrone in refractory non\u2010Hodgkin's lymphoma: A Southwest Oncology Group study","volume":"11","author":"Coltman CA","year":"1984","journal-title":"Semin Oncol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100313"},{"key":"e_1_2_6_13_2","volume-title":"Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_14_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.021311"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00258-K"},{"key":"e_1_2_6_20_2","first-page":"27","article-title":"Irinotecan in relapsed or refractory non\u2010Hodgkin's lymphomas: Indications of activity in a phase II trial","volume":"16","author":"Sarris AH","year":"2002","journal-title":"Oncology"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000099643"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2002.00951.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0615-3"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.68.163"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00249.x"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2006.00349.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2006.00349.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:05:40Z","timestamp":1697378740000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2006.00349.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,17]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1349-7006.2006.00349.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00349.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,17]]}}}